Overview

Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
0
Participant gender:
All
Summary
This clinical trial compares a combination of two drugs that constrict blood vessels (Octreotide LAR and Midodrine) to albumin after large volume paracentesis. Subjects have cirrhosis and ascites.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
US Department of Veterans Affairs
VA Office of Research and Development
Treatments:
Midodrine
Octreotide
Vasoconstrictor Agents
Criteria
Inclusion Criteria:

- Cirrhosis of any etiology

- Age 18-80 years

- Moderate to severe ascites

Exclusion Criteria:

- No or small ascites

- Severe hepatic hydrothorax

- Recent GI (gastrointestinal) hemorrhage

- Active bacterial infection

- Cardiac failure

- Organic renal disease

- Hepatocellular carcinoma

- Severe comorbidity (advanced neoplasia)

- Serum creatinine > 3 mg/dl

- Pregnancy